Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Thymosin Alpha-1: Evidence Summary
Evidence summary for Thymosin Alpha-1 across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Thymosin Alpha-1 overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Hepatitis B/C | Tier A | 15 | Approved in multiple countries for viral hepatitis |
| Immune support (cancer adjunct) | Tier B | 10 | Used as immune adjuvant in oncology settings |
| Vaccine enhancement | Tier C | 5 | Limited trials showing improved vaccine response |